Goéré Diane, Sourrouille Isabelle, Gelli Maximiliano, Benhaim Léonor, Faron Matthieu, Honoré Charles
Department of Visceral and Oncological Surgery, Gustave Roussy, Cancer Campus, Villejuif Cedex 94805, France.
Department of Visceral and Oncological Surgery, Gustave Roussy, Cancer Campus, Villejuif Cedex 94805, France.
Surg Oncol Clin N Am. 2018 Jul;27(3):563-583. doi: 10.1016/j.soc.2018.02.011.
Peritoneal metastases are the third most common site of recurrence of colorectal cancer. Diagnosis is difficult and often made at an advanced stage even on imaging. Curative treatment relies on complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC), which dramatically improves survival in selected patients. Main prognostic factors are based on the extent of the peritoneal disease and the completeness of surgery. Therefore, identifying patients at high risk of developing peritoneal metastases with the aim of diagnosing and treating patients at an early stage appears crucial. Proactive attitude and prophylactic treatment based on HIPEC are being evaluated on clinical trials.
腹膜转移是结直肠癌复发的第三大常见部位。诊断困难，即使通过影像学检查往往也在晚期才能确诊。根治性治疗依赖于完全细胞减灭术加腹腔内热灌注化疗（HIPEC），这可显著提高特定患者的生存率。主要预后因素基于腹膜疾病的范围和手术的完整性。因此，识别有发生腹膜转移高风险的患者，以便早期诊断和治疗显得至关重要。基于HIPEC的积极态度和预防性治疗正在临床试验中进行评估。
